GL1X · GenesisL1 explorer

MolNFT v1 · #97474 · protein

Structure of the P4509 BM3 A82F F87V heme domain

4KF2 · Bifunctional P-450/NADPH-P450 reductase: “Structure of the P4509 BM3 A82F F87V heme domain”. X-ray diffraction, 1 ligand (HEM), 7 pockets (best druggability 0.87). MolNFT v1 #97474 on GenesisL1: 3D structure, binding sites and…

PDB
4KF2
Type
protein
Length
899 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Bifunctional P-450/NADPH-P450 reductase
EC
1.14.14.1, 1.6.2.4
UniProt
P14779
Ligands
HEM
Pockets
7 · best druggability 0.87

Structure

x-ray diffraction · 2 distinct chains · 55% helix, 11% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ABifunctional P-450/NADPH-P450 reductase (EC 1.14.14.1, 1.6.2.4)protein45155% helix, 12% strandP14779
BBifunctional P-450/NADPH-P450 reductase (EC 1.14.14.1, 1.6.2.4)protein44855% helix, 11% strandP14779

Ligands and binding sites

  • HEM · Protoporphyrin IX containing Fe · ligand · 2 copies · chains A, B
  • IMD · Imidazole · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111240.870.88104HEM, IMD
211470.850.85101HEM, IMD
31480.590.8321empty
42820.530.7531empty
52340.470.7329empty

Interfaces

1 interface between chains.

  • A–B · 529 Ų buried · 7 hydrogen bonds · protein-protein

Compared structures

  • 4KF2 · Structure of the P4509 BM3 A82F F87V heme domain · the same entry in another collection · chain A against A, TM-score 1.00
  • P14779 · AlphaFold monomer V2.0 prediction for bifunctional cytochrome P450/NADPH--P450 reductase… · a predicted model of the same protein · chain B against A, TM-score 0.97

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.